Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matt Miksic
BARC
Matt Miksic
Wall Street Analyst
★★☆☆☆
#2283
on 13Foresight · ranked by our own returns
34%
Success Rate
-9.3%
Average Return
13 of 38 calls profitable · -12.7% vs benchmark
📈 Across the calls we could measure, roughly 34% of Matt Miksic's ratings turned a profit when each position was held for 1 year — averaging -9.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

117 Buy 48 Hold 12 Sell
Matt's Stock Coverage 40 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
BSX
Boston Scientific
May 28, 2026 BUY Strong Buy
+73.0% avg upside
38 analysts
$89.00
97.92% Upside
-7.7%
PODD
Insulet
May 28, 2026 SELL Strong Buy
+79.3% avg upside
32 analysts
$198.00
37.89% Upside
-4.9%
DXCM
Dexcom
May 18, 2026 SELL Strong Buy
+38.8% avg upside
32 analysts
$64.00
10.13% Downside
-12.4%
AVR
Anteris Technologies Global Corp.
May 15, 2026 BUY Strong Buy
+50.4% avg upside
5 analysts
$18.00
89.55% Upside
+19.1%
JNJ
Johnson & Johnson
May 13, 2026 HOLD Strong Buy
-3.6% avg upside
36 analysts
$255.00
8.82% Upside
+2.6%
HUMA
Humacyte
May 13, 2026 BUY Strong Buy
+654.7% avg upside
11 analysts
$1.50
54.82% Upside
-6.6%
OBIO
Orchestra BioMed Holdings
May 13, 2026 BUY Strong Buy
+234.3% avg upside
9 analysts
$13.00
235.82% Upside
+1.2%
BDX
Becton Dickinson
May 11, 2026 BUY Buy
+35.6% avg upside
25 analysts
$204.00
44.13% Upside
+1.3%
SENS
Senseonics Holdings
May 11, 2026 BUY Buy
+125.2% avg upside
13 analysts
$31.00
363.43% Upside
+0.0%
GMED
Globus Medical
May 11, 2026 BUY Strong Buy
+22.3% avg upside
24 analysts
$123.00
63.11% Upside
+4.8%
TNDM
Tandem Diabetes Care
May 08, 2026 BUY Buy
+115.3% avg upside
29 analysts
$55.00
257.16% Upside
+9.2%
INMD
InMode
May 07, 2026 BUY Buy
+41.9% avg upside
9 analysts
$19.00
42.12% Upside
-4.0%
LIVN
LivaNova
May 07, 2026 HOLD Strong Buy
+0.2% avg upside
14 analysts
$76.00
3.10% Downside
-1.3%
CH:ALC
Alcon
May 06, 2026 HOLD Buy
+34.9% avg upside
35 analysts
$62.28
20.26% Upside
·
ATEC
Alphatec Holdings
May 06, 2026 BUY Strong Buy
+116.6% avg upside
22 analysts
$24.00
191.36% Upside
+15.7%
BAX
Baxter International
May 04, 2026 BUY Hold
+50.4% avg upside
23 analysts
$27.00
39.33% Upside
+25.3%
SYK
Stryker
May 01, 2026 BUY Strong Buy
+24.1% avg upside
36 analysts
$394.00
30.85% Upside
+3.0%
GEHC
GE Healthcare Technologies Inc
Apr 30, 2026 HOLD Strong Buy
+36.1% avg upside
20 analysts
$78.00
27.58% Upside
+1.2%
BLCO
Bausch + Lomb Corporation
Apr 30, 2026 HOLD Buy
+30.6% avg upside
19 analysts
$20.00
34.68% Upside
-4.5%
ZBH
Zimmer Biomet Holdings
Apr 29, 2026 SELL Buy
+27.6% avg upside
37 analysts
$94.00
7.90% Upside
-10.8%
EW
Edwards Lifesciences
Apr 24, 2026 BUY Strong Buy
+11.7% avg upside
34 analysts
$110.00
26.95% Upside
+3.0%
ISRG
Intuitive Surgical
Apr 23, 2026 BUY Strong Buy
+29.5% avg upside
36 analysts
$651.00
61.84% Upside
-15.0%
ABT
Abbott Laboratories
Apr 20, 2026 BUY Strong Buy
+31.2% avg upside
35 analysts
$143.00
61.60% Upside
-7.8%
MDT
Medtronic
Apr 01, 2026 BUY Buy
+23.7% avg upside
38 analysts
$120.00
53.66% Upside
-7.8%
MMED
MiniMed Group, Inc.
Mar 31, 2026 BUY Strong Buy
+48.5% avg upside
13 analysts
$26.00
83.57% Upside
·
COO
Cooper Co
Mar 24, 2026 BUY Buy
+102.5% avg upside
21 analysts
$103.00
58.24% Upside
-4.5%
ORGO
Organogenesis Holdings
May 11, 2022 BUY Strong Buy
+385.9% avg upside
8 analysts
$25.00
968.32% Upside
-51.0%
ALGN
Align Tech
May 04, 2022 BUY Strong Buy
+58.0% avg upside
21 analysts
$418.00
140.79% Upside
-2.2%
RBOT
Vicarious Surgical
Mar 04, 2022 BUY Buy
+5297.1% avg upside
6 analysts
$13.00
5401.50% Upside
·
SDCCQ
SmileDirectClub
Mar 03, 2022 BUY Sell
+513999900.0% avg upside
10 analysts
$20.00
1999999899.96% Upside
-74.5%
SHC
Sotera Health
Mar 02, 2022 BUY Strong Buy
+30.3% avg upside
13 analysts
$28.00
81.17% Upside
-13.1%
XRAY
DENTSPLY SIRONA
Mar 01, 2022 BUY Buy
+171.7% avg upside
25 analysts
$67.00
568.02% Upside
-30.3%
HSIC
Henry Schein
Feb 16, 2022 BUY Buy
+7.4% avg upside
25 analysts
$100.00
25.02% Upside
-1.7%
IART
Integra Lifesciences
Nov 03, 2021 BUY Buy
+137.0% avg upside
21 analysts
$87.00
405.87% Upside
-32.3%
NVST
Envista Holdings
Sep 30, 2021 BUY Buy
+13.6% avg upside
19 analysts
$55.00
121.18% Upside
-21.5%
MDXG
MiMedx Group
Dec 12, 2016 SELL Strong Buy
+185.0% avg upside
17 analysts
$9.00
149.35% Upside
-34.5%
HIND
Vyome Holdings
Oct 31, 2016 BUY Strong Buy
+1347.8% avg upside
8 analysts
$21.00
863.22% Upside
-34.8%
SNN
Smith & Nephew Snats
Nov 03, 2014 HOLD Buy
+11.8% avg upside
14 analysts
$37.00
23.00% Upside
+3.5%
CNMD
Conmed
Jul 24, 2013 HOLD Hold
+81.5% avg upside
12 analysts
$36.00
12.08% Upside
+19.7%
OFIX
Orthofix Medical
Mar 14, 2013 HOLD Strong Buy
+209.2% avg upside
15 analysts
$43.00
365.83% Upside
-35.4%
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Matt Miksic — Frequently Asked Questions
How accurate are Matt Miksic's stock ratings?
Based on the calls 13Foresight could measure, about 34% of Matt's ratings were profitable over a one-year hold, with an average return of -9.3% per rating, or -12.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Matt ranked on 13Foresight?
Matt Miksic is currently ranked #2283 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matt cover?
Matt most recently has ratings on BSX, PODD, DXCM, AVR, JNJ, HUMA, OBIO, BDX, SENS, GMED, TNDM, INMD and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.